Aduro Biotech Inc. (ADRO) Receives Consensus Rating of “Hold” from Brokerages
Aduro Biotech Inc. (NASDAQ:ADRO) has been given an average rating of “Hold” by the eight brokerages that are currently covering the firm. Two investment analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $20.00.
A number of equities research analysts have weighed in on the company. Roth Capital restated a “buy” rating and set a $22.00 price target on shares of Aduro Biotech in a research report on Monday, July 11th. Canaccord Genuity restated a “buy” rating and set a $30.00 price target on shares of Aduro Biotech in a research report on Friday, August 5th. Finally, Zacks Investment Research downgraded Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Monday, July 18th.
Aduro Biotech (NASDAQ:ADRO) traded down 2.33% on Monday, reaching $11.33. The company had a trading volume of 203,992 shares. The firm’s market capitalization is $733.66 million. The company’s 50 day moving average is $13.65 and its 200-day moving average is $13.10. Aduro Biotech has a one year low of $7.26 and a one year high of $34.95.
Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Wednesday, August 3rd. The company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.21. Aduro Biotech had a negative return on equity of 9.23% and a negative net margin of 23.69%. The business had revenue of $39 million for the quarter, compared to the consensus estimate of $25.24 million. The business’s revenue was up 306.3% compared to the same quarter last year. On average, equities research analysts expect that Aduro Biotech will post ($1.39) earnings per share for the current fiscal year.
In related news, insider Thomas W. Dubensky sold 25,000 shares of the firm’s stock in a transaction dated Monday, October 3rd. The stock was sold at an average price of $12.68, for a total value of $317,000.00. Following the sale, the insider now directly owns 55,424 shares of the company’s stock, valued at $702,776.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jennifer Lew sold 6,360 shares of the firm’s stock in a transaction dated Monday, September 19th. The stock was sold at an average price of $14.95, for a total value of $95,082.00. Following the completion of the sale, the insider now directly owns 48,955 shares in the company, valued at $731,877.25. The disclosure for this sale can be found here. 6.50% of the stock is owned by corporate insiders.
Several hedge funds have recently bought and sold shares of ADRO. Vanguard Group Inc. boosted its stake in Aduro Biotech by 15.3% in the second quarter. Vanguard Group Inc. now owns 1,794,838 shares of the company’s stock valued at $20,300,000 after buying an additional 237,924 shares during the last quarter. BlackRock Fund Advisors boosted its stake in Aduro Biotech by 62.0% in the second quarter. BlackRock Fund Advisors now owns 1,665,187 shares of the company’s stock valued at $18,833,000 after buying an additional 637,486 shares during the last quarter. Franklin Resources Inc. boosted its stake in Aduro Biotech by 0.6% in the first quarter. Franklin Resources Inc. now owns 893,210 shares of the company’s stock valued at $11,442,000 after buying an additional 5,527 shares during the last quarter. State Street Corp boosted its stake in Aduro Biotech by 237.9% in the second quarter. State Street Corp now owns 543,514 shares of the company’s stock valued at $6,147,000 after buying an additional 382,654 shares during the last quarter. Finally, BVF Inc. IL acquired a new stake in Aduro Biotech during the second quarter valued at about $5,809,000. 29.75% of the stock is currently owned by institutional investors.
About Aduro Biotech
Aduro Biotech, Inc is a clinical-stage immunotherapy company. The Company is focused on the discovery, development and commercialization of therapies that transform the treatment of various diseases. The Company has developed approximately three technology platforms, which include Live, Attenuated, Double-Deleted (LADD), Stimulator of Interferon Genes (STING) Pathway Activator and B-select monoclonal antibodies.
Receive News & Stock Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related stocks with our FREE daily email newsletter.